IV busulfan dose individualization in children undergoing hematopoietic stem cell transplant:: Limited sampling strategies

被引:33
作者
Dupuis, L. Lee [1 ,2 ,3 ,4 ]
Sibbald, Cathryn [1 ]
Schechter, Tal
Ansari, Marc [5 ]
Gassas, Adam [3 ]
Theoret, Yves [6 ,8 ]
Kassir, Nastya [9 ]
Champagne, Martin A. [5 ,7 ]
Doyle, John [3 ,4 ]
机构
[1] Hosp Sick Children, Dept Pharm, Toronto, ON M5G 1X8, Canada
[2] Univ Toronto, Leslie Dan Fac Pharm, Toronto, ON M5S 1A1, Canada
[3] Hosp Sick Children, Div Haematol Oncol, Toronto, ON M5G 1X8, Canada
[4] Hosp Sick Children, Res Inst, Toronto, ON M5G 1X8, Canada
[5] Univ Montreal, Div Haematol & Oncol, Montreal, PQ, Canada
[6] Univ Montreal, Dept Clin Biochem, CHU Ste Justine, Montreal, PQ, Canada
[7] Univ Montreal, Dept Pediat, Montreal, PQ, Canada
[8] Univ Montreal, Dept Pharmacol, Montreal, PQ, Canada
[9] Univ Montreal, Fac Pharm, Montreal, PQ, Canada
关键词
busulfan; area under the curve; pediatrics; pharmacokinetics; limited sampling strategy;
D O I
10.1016/j.bbmt.2008.03.002
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
We currently calculate area under the busulfan concentration time curve (AUC) using 7 plasma busulfan concentrations (AUC7) drawn after the first of 16 i.v. busulfan doses given as a 2-hour infusion every 6 hours. The aim of this study was to develop and validate limited sampling strategies (LSSs) using 3 or fewer busulfan concentration values with which to reliably calculate AUC in children undergoing hematopoietic stem cell transplant (HSCT). Children in the development group (44) received i.v. busulfan at Sick Kids; the validation group consisted of 35 children who received care at CHU Ste-Justine. Busulfan doses given and subsequent plasma busulfan concentrations were recorded. LSSs using 1 to 3 concentration-time, points were developed using multiple linear regression. LSS were considered to be acceptable when adjusted r(2) > 0.9, mean bias <15% and precision <15%. Extent of agreement between the AUC7 values and the LSS AUC was assessed by the intraclass correlation coefficient (ICC) and Bland-Altman (BA) analysis. Agreement was considered to be excellent when the lower limit of the 95% confidence limit of the ICC exceeded 0.9 and when the limits of agreement in the BA analysis were +/- 15% for both AUC and dose. Administration of the theoretic adjusted busulfan doses based on each LSS was simulated and cases where the resulting AUC was >1500 or <900 mu M.min were noted. LSSs using 1, 2, or 3 plasma busulfan concentrations were developed that showed excellent agreement with AUC7 and adjusted busulfan doses. In the validation sample, only the 2- and 3-point LSSs demonstrated acceptable precision and lack of bias. LSSs using 2 or 3 plasma busulfan concentrations can be used to reliably estimate busulfan AUC after IN administration in children undergoing HSCT. (C) 2008 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:576 / 582
页数:7
相关论文
共 10 条
[1]
STATISTICAL METHODS FOR ASSESSING AGREEMENT BETWEEN TWO METHODS OF CLINICAL MEASUREMENT [J].
BLAND, JM ;
ALTMAN, DG .
LANCET, 1986, 1 (8476) :307-310
[2]
DETERMINATION OF BUSULFAN IN HUMAN-PLASMA BY GAS-CHROMATOGRAPHY WITH ELECTRON-CAPTURE DETECTION [J].
CHEN, TL ;
GROCHOW, LB ;
HUROWITZ, LA ;
BRUNDRETT, RB .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1988, 425 (02) :303-309
[3]
Dix SP, 1996, BONE MARROW TRANSPL, V17, P225
[4]
GROCHOW LB, 1993, SEMIN ONCOL, V20, P18
[5]
GAS-CHROMATOGRAPHIC DETERMINATION OF BUSULFAN IN PLASMA WITH ELECTRON-CAPTURE DETECTION [J].
HASSAN, M ;
EHRSSON, H .
JOURNAL OF CHROMATOGRAPHY, 1983, 277 (OCT) :374-380
[6]
Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study [J].
Nguyen, L ;
Leger, F ;
Lennon, S ;
Puozzo, C .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (02) :191-198
[7]
Measurement of plasma busulfan concentration by high-performance liquid chromatography with ultraviolet detection [J].
Rifai, N ;
Sakamoto, M ;
Lafi, M ;
Guinan, E .
THERAPEUTIC DRUG MONITORING, 1997, 19 (02) :169-174
[8]
SLATTERY JT, 1995, BONE MARROW TRANSPL, V16, P31
[9]
Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation [J].
Slattery, JT ;
Clift, RA ;
Buckner, CD ;
Radich, J ;
Storer, B ;
Bensinger, WI ;
Soll, E ;
Anasetti, C ;
Bowden, R ;
Bryant, E ;
Chauncey, T ;
Deeg, HJ ;
Doney, KC ;
Flowers, M ;
Gooley, T ;
Hansen, JA ;
Martin, PJ ;
McDonald, GB ;
Nash, R ;
Petersdorf, EW ;
Sanders, JE ;
Schoch, G ;
Stewart, P ;
Storb, R ;
Sullivan, KM ;
Thomas, ED ;
Witherspoon, RP ;
Appelbaum, FR .
BLOOD, 1997, 89 (08) :3055-3060
[10]
A limited sampling strategy for pharmacokinetic directed therapy with intravenous busulfan [J].
Vaughan, WP ;
Carey, D ;
Perry, S ;
Westfall, AO ;
Salzman, DE .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2002, 8 (11) :619-624